SCHEMBL4367490

SCHEMBL4367490

N[C@@H](C(=O)O)C(CC(=O)O)Cc1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC1A3 P43003 4/20 0.61
SLC1A2 P43004 4/20 0.61
SLC1A1 P43005 4/20 0.61
CPA1 P15085 2/20 0.58
CPA3 P15088 2/20 0.58
CPB1 P15086 1/20 0.58
CPB2 Q96IY4 1/20 0.58
ALPI P09923 1/20 0.56
PKM P14618 1/20 0.56
PTGS1 P23219 1/20 0.56
XIAP P98170 1/20 0.56
SLC7A5 Q01650 1/20 0.56
CYP1A2 P05177 2/20 0.50
SLC15A1 P46059 1/20 0.49
MEN1 O00255 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
KMT2A Q03164 1/20 0.47
SRR Q9GZT4 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1101111 1.00 SLC1A3 (0.61) SLC1A3SLC1A2SLC1A1CPA1CPA3
SCHEMBL27348648 0.89 SLC1A3 (0.69) SLC1A3SLC1A2SLC1A1CPA1CPA3
SCHEMBL5081348 0.85 CPA3 (0.64) CPA1CPA3CPB1CPB2ALPI
SCHEMBL5081346 0.85 CPA3 (0.64) CPA1CPA3CPB1CPB2ALPI
SCHEMBL2890748 0.84 SLC1A3 (0.62) SLC1A3SLC1A2SLC1A1CPA1CPA3
SCHEMBL2890750 0.84 SLC1A3 (0.62) SLC1A3SLC1A2SLC1A1CPA1CPA3
SCHEMBL14420246 0.82 SLC1A3 (0.61) SLC1A3SLC1A2SLC1A1CPA1ALPI
SCHEMBL27644705 0.82 SLC1A3 (0.61) SLC1A3SLC1A2SLC1A1CPA1ALPI
SCHEMBL14420344 0.82 SLC1A3 (0.61) SLC1A3SLC1A2SLC1A1CPA1ALPI
SCHEMBL27348647 0.81 CPA1 (0.51) SLC1A3SLC1A2SLC1A1CPA1CPA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103338751-A A pharmaceutical composition UNIV WITWATERSRAND JHB 2013-10-02 CN claimed
EP-1203784-B1 POLYMER, IN VIVO DEGRADABLE MATERIAL, AND USE NOF CORP (JP) 2008-12-10 EP claimed
EP-1203784-A1 POLYMER, IN VIVO DEGRADABLE MATERIAL, AND USE NOF CORPORATION (JP) 2002-05-08 EP claimed
US-20210015770-A1 THERMORESPONSIVE HYDROGEL CONTAINING POLYMER MICROPARTICLES FOR CONTROLLED DRUG DELIVERY TO THE EAR UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2021-01-21 US disclosed
US-8853167-B2 Short-chain cationic polyamino acid and use thereof NANOCARRIER CO., LTD. (JP) 2014-10-07 US disclosed
EP-2397487-B1 SHORT-CHAIN CATIONIC POLYAMINO ACID AND USE THEREOF NANOCARRIER CO LTD (JP) 2013-12-25 EP disclosed
CN-103338751-A A pharmaceutical composition UNIV WITWATERSRAND JHB 2013-10-02 CN disclosed
CN-102791255-A Micelle compositions and process for the preparation thereof DSM IP ASSETS BV 2012-11-21 CN disclosed
US-8211351-B2 Resorbable polymeric medical goods with improved mechanical properties and method for producing same SYNTHES USA, LLC (US) 2012-07-03 US disclosed
US-20120149649-A1 SHORT-CHAIN CATIONIC POLYAMINO ACID AND USE THEREOF THE UNIVERSITY OF TOKYO (JP) 2012-06-14 US disclosed
EP-2397487-A1 SHORT-CHAIN CATIONIC POLYAMINO ACID AND USE THEREOF NanoCarrier Co., Ltd. (JP) 2011-12-21 EP disclosed
US-20090030415-A1 RESORBABLE POLYMERIC MEDICAL GOODS WITH IMPROVED MECHANICAL PROPERTIES AND METHOD FOR PRODUCING SAME SYNTHES USA, LLC 2009-01-29 US disclosed
EP-1203784-B1 POLYMER, IN VIVO DEGRADABLE MATERIAL, AND USE NOF CORP (JP) 2008-12-10 EP disclosed
EP-1744792-A1 RESORBABLE POLYMERIC MEDICAL GOODS WITH IMPROVED MECHANICAL PROPERTIES AND METHOD FOR PRODUCING SAME Synthes GmbH (CH) 2007-01-24 EP disclosed
WO-2005110506-A1 RESORBABLE POLYMERIC MEDICAL GOODS WITH IMPROVED MECHANICAL PROPERTIES AND METHOD FOR PRODUCING SAME SYNTHES GMBH (CH) 2005-11-24 WO disclosed
US-6673361-B1 BLOCK COPOLYMER COMPRISING POLYETHYLENE GLYCOL BONDED WITH MODIFIED AMINO ACID SEGMENTS; FILM FOR PREVENTING TISSUE ADHESION, ARTIFICIAL DURA MATER, SUTURES, IMPLANTS, OR BIODEGRADABLE SUSTAINED-RELEASE DRUG FOUNDATION NOF CORPORATION (JP) 2004-01-06 US disclosed
EP-1203784-A1 POLYMER, IN VIVO DEGRADABLE MATERIAL, AND USE NOF CORPORATION (JP) 2002-05-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149649-A1 SHORT-CHAIN CATIONIC POLYAMINO ACID AND USE THEREOF SLC7A1, SLC1A5, SLC43A1 SLC1A3 37/4885SLC1A2 40/4885SLC1A1 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.